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Abstract: Bacterial conjunctivitis is a common infectious disease of the eye, characterized by 
conjunctival hyperemia, eyelid edema, and purulent discharge. Although the prevalence and 
incidence are not well reported, bacterial conjunctivitis represents one of the most frequent 
causes of patient visits to both primary care physicians and ophthalmologists. Most cases of 
nongonococcal and nonchlamydial bacterial conjunctivitis are self-limiting and may resolve 
without intervention. There is a place for treatment, however, which allows for a shorter time to 
clinical and microbiological resolution which may decrease the mild morbidity, decrease health 
care costs of visits and potential complications, return patients back to school or the work force, 
and limit the potential spread of this communicable infection. Gatifloxacin ophthalmic solu-
tion is a broad spectrum 8-methoxyfluroroquinolone bactericidal antibiotic, with good activity 
against Staphylococcus aureus, Streptococcus species, and Gram-negative pathogens. It also 
has a relatively good resistance profile, making it a more than adequate choice in the treatment 
of bacterial conjunctivitis when therapy is warranted.
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Introduction
Conjunctivitis, or inflammation of the conjunctiva, refers to a diverse group of diseases 
or disorders that primarily affect the conjunctiva. It can be broadly classified as infec-
tious or noninfectious, with infectious etiologies of conjunctivitis caused by viruses, 
fungi, parasites, and bacteria. Conjunctivitis can also be further classified as acute, 
chronic, or recurrent. A hyperacute form of mucopurulent conjunctivitis also exists 
which is specifically caused by infection from Neisseria gonorrhea.
Epidemiology
Collectively, conjunctivitis represents one of the most frequent causes of patient visits 
to ophthalmologists and other health care personnel, including optometrists, emergency 
physicians, pediatricians, family physicians, and internists.1 The incidence of bacte-
rial conjunctivitis is difficult to determine because most cases of infectious bacterial 
conjunctivitis are self-limiting, and many cases are treated empirically without cultures 
by physicians in specialties outside of ophthalmology.2
Most cases of bacterial conjunctivitis are caused by Gram-positive commensal 
organisms that are part of the normal skin flora. In 1975, Perkins et al reported results 
of isolates from 267 eyes with conjunctivitis. Staphylococcus epidermidis was the 
aerobic organism most often observed (67.8%), followed by Staphylococcus aureus 
(23.1%). Propionibacterium acnes was the most commonly isolated anaerobic bacteria 





(46.2%) followed by Peptostreptococcus species (29.3%).3 
Similarly, Brook et al reported a series of positive cultures 
from 120 patients with acute conjunctivitis presenting over 
a three-month period at the end of 1975. S. epidermidis 
(49.6%) was the organism most frequently isolated from eyes 
with inflamed conjunctiva, followed by Propionibacterium 
(22.9%), Diphtheroids (18.3%), and S. aureus (17.5%).4 
In 1995, Everett et al reported 385 bacterial isolates from 
patients with bacterial conjunctivitis over a one-year period. 
Gram-positive organisms accounted for 75% of the isolates, 
with coagulase-negative staphylococci and S. aureus being 
the two most commonly found (39% and 21%, respectively).5 
More recently, Cavuoto et al reported results from 1254 
culture-positive isolates identified from 2408 consecutive 
conjunctival cultures evaluated for acute bacterial conjuncti-
vitis between 1994 and 2003. S. aureus was the most frequent 
isolate (37.6%).6
In addition to skin flora, Gram-negative organisms, 
specifically Haemophilus influenzae, may be a significant 
etiology of bacterial conjunctivitis, especially in children. 
Brook compared organisms recovered from 119 children 
with conjunctivitis with 60 controls. The organisms found 
more frequently in inflamed eyes as compared with normal 
eyes were S. aureus (P , 0.05), Streptococcus pneumoniae 
(P , 0.002), and H. influenzae (P , 0.001).4 Gigliotti et al 
found a similar result when they compared conjunctival 
cultures of 99 patients with conjunctivitis with 102 age- 
and  season-matched controls. The two organisms most 
statistically associated with bacterial conjunctivitis were 
H. influenzae (42% versus 0%) and S. pneumoniae (12% 
versus 3%).7
Length of stay in neonatal intensive care units has 
been shown to affect isolates of nongonococcal and non-
chlamydial causes of bacterial conjunctivitis in neonates. 
Longer admission stays were associated with higher rates of 
 Gram-positive pathogens, especially methicillin-susceptible 
S. aureus (MSSA) and Enterococcus species. Pseudomonas 
aeruginosa and Serratia marcescens were frequent isolates 
after the first 10 days of admission, presumably from iatro-
genic transmission. Conversely, longer stays were associated 
with decreasing frequency of Klebsiella pneumoniae and 
Escherichia coli, which presumably were acquired early from 
vertical transmission.8
In the largest series of conjunctival cultures ever published, 
Abedayo et al reported the results of 12,134 positive cultures 
from 20,180 cultures for presumed bacterial conjunctivitis 
over an 11.5-year period. S. aureus was the most commonly 
identified isolate (38.7%). Of these,  methicillin-resistant 
S. aureus (MRSA) comprised about 30%. The next most 
common organisms were S. viridans (8.1%), S. pneumoniae 
(7.6%), H. influenzae (6.9%), P. aeruginosa (4.8%), and 
S. marcescens (2.4%). Positive biennial increases were noted 
for S. aureus (+2.78%), S. pneumoniae (+0.87%), S. viridans 
(+1.55%), and P. aeruginosa (+1.94%).9
Clinical presentation
Predisposing factors for developing bacterial conjunctivitis 
include contact with an infected individual, oculogenital 
spread, infection or abnormality of adnexal structures, lid 
malposition, severe tear deficiency, immunosuppression, 
and trauma. Infants and children may have nasolacrimal duct 
obstruction, concomitant bacterial otitis media or pharyngitis, 
or nasopharyngeal bacterial colonization as well. Neonates 
might acquire organisms from an infected mother or from 
inadequate prenatal care.10 Clinical signs include purulent 
discharge, eyelid edema, conjunctival hyperemia, conjuncti-
val membranes or pseudomembranes, papillary hypertrophy, 
and follicular hyperplasia.2
Positive bacterial cultures in children with acute conjunc-
tivitis have been associated with a history of sticky eyelids/
eyelashes in the morning, mucoid or purulent eye discharge, 
and examination findings of crusting or gluing of the eyelids/
eyelashes, lack of sensation of burning eyes, and the absence 
of watery discharge.11 In a prospective study of 428 children 
aged 2–36 months diagnosed with acute conjunctivitis in 
Israel, clinical signs were associated with pathogen cultures. 
Recurrent conjunctivitis was more common in patients with 
cultures yielding more than one pathogen. H. influenzae was 
associated with fever and concomitant acute otitis media. 
H. influenzae was also more associated with bilateral bacte-
rial conjunctivitis compared with S. pneumoniae or mixed 
infection.12
Natural history
Cases of bacterial conjunctivitis in developed countries tend to 
be self-limiting in adults and rarely lead to serious long-term 
complications. Two exceptions to this are  Staphylococcus13 
and Moraxella.14 In either case, the organisms colonize the 
skin of the eyelid, which may be a risk factor for  chronicity.2 
Untreated cases may continue to persist, and possibly cause 
severe damage, such as corneal infection.15,16
Why we treat conjunctivitis
Although most cases of bacterial conjunctivitis might 
improve without treatment, instilling antibiotic therapy can 
reduce the duration of signs and symptoms by a significant 
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amount. A meta-analysis by Sheik and Hurwitz consisting of 
1034 patients in five double-blind, placebo-controlled trials 
suggested that topical antibiotics are of benefit in improving 
early (days 2–5) and late (days–10) clinical and microbiologi-
cal remission in patients with bacterial conjunctivitis. They 
state that acute bacterial conjunctivitis is frequently a self-
limiting condition, because clinical cure/significant improve-
ment occurred by days 2–5 in 65% (95% confidence interval 
[CI] 59%–70%) of those treated with placebo. Meta-analysis 
of early (days 2–5) and late (days 6–10) clinical and 
microbiological outcomes revealed that topical antibiotics are 
of benefit in improving early clinical (risk ratio [RR] 1.24; 
95% CI 1.05–1.45) and microbiological (RR 1.77; 95% 
CI 1.23–2.54) remission. These benefits were reduced, but 
nonetheless persisted, for late clinical (RR 1.11; 95% CI 
1.02–1.21) and microbiological (RR 1.56; 95% CI 1.17–2.09) 
remission. Results from this meta-analysis show that the 
number needed to treat for early clinical remission was six, 
and for late clinical remission was 13.17 Given the relatively 
high incidence of bacterial conjunctivitis, a shortened clinical 
course may have socioeconomic benefits, such as limiting 
the number of days children are unable to return to school 
until they are either treated or cured. There may also be a 
trickle-down effect because parents who may have had to 
take days off work to watch children who had to stay home 
from school, or babysitters/nannies who needed to be hired 
for the days off school also impact the family social unit 
negatively.18
Treatment of conjunctivitis
Antibiotic therapy consists of a broad-spectrum agent when 
the organism is not known or targeted therapy after identifica-
tion and susceptibilities of the pathogen have been achieved. 
Conjunctivitis due to Chlamydia and gonococcal species, 
and complicated H. influenzae conjunctivitis in children 
associated with acute otitis media, requires systemic therapy. 
Many randomized, controlled studies of topical antibiotic 
treatments for conjunctivitis have been published, and almost 
all of the trials showed little difference in efficacy between 
the comparative agents.19,20 An exception is one study pub-
lished in 1983 that showed chloramphenicol to be inferior 
to combinations of neomycin-polymyxin B-gramicidin and 
trimethoprim-polymyxin B.21
Treatment of acute infectious conjunctivitis in adults 
is often started empirically at the time of presentation, and 
often without pursuit of etiology. Results from a survey of 
general practitioners in the UK showed that 95% usually pre-
scribe topical antibiotics for acute infectious conjunctivitis. 
Of those surveyed, 67% have never pursued culture of the 
infection. It also reported that 46% used a delayed prescrip-
tion strategy (providing a prescription to use if required after 
a few days).22 Delaying antibiotic treatment has been shown 
to reduce antibiotic use and reduce patient revisits for eye 
infections, with similar duration and severity of symptoms 
when compared with immediate prescribing.23 These findings 
reflect a common practice of prescribing antibiotics when it 
may not be completely necessary, which might contribute 
to the selection of resistant organisms.
Emerging resistance  
in microbiology and conjunctivitis
In 2003, Kowalski et al reported trends of emerging resis-
tance of bacterial pathogens isolated from endophthalmitis, 
keratitis, conjunctivitis, and blepharitis to commonly used 
antibiotics over a nine-year period. Coagulase-negative 
staphylococci isolated from patients with blepharitis showed 
an increased trend of erythromycin resistance, with a sus-
ceptibility of 61% in 1993 compared with 20% in 2001; 
susceptibility to second-generation fluoroquinolones for 
conjunctivitis and blepharitis isolates was 100% in 1993, 
25% in 1999, and 70% in 2001. Similar trends for second-
generation fluoroquinolones were seen in S. aureus isolates. 
For all pathologies, the susceptibility was over 90% in 1993, 
but decreased to 70% for conjunctivitis and blepharitis, to 
50% for keratitis, and to 0% for endophthalmitis in 2001.24
The Ocular Tracking Resistance in the US Today 
(TRUST) program purports to monitor in vitro susceptibility 
of pathogens isolated from ocular infections. Its first annual 
survey, Ocular TRUST I, reported the results of prospectively 
surveyed in vitro susceptibility testing (the data  however, was 
retrospectively reported from those centers who answered 
the survey) from October 2005 through June 2006 for 
isolates of S. aureus, S. pneumoniae, and H. influenzae. 
They showed that although fluoroquinolones were 
active against MSSA, most MRSA isolates exhibited high-
level resistance to the class and other drugs tested. Among 
the S. pneumoniae  isolates, all showed high susceptibility 
to the fluoroquinolones, with 100% in vitro susceptibility to 
levofloxacin, gatifloxacin, and moxifloxacin. Although 44% 
of the H. influenzae isolates were beta-lactamase-positive, all 
isolates were susceptible to the antibiotics tested.25
A retrospective cross-sectional study examining organ-
ism and antibiotic susceptibility trends in patients with 
bacterial conjunctivitis from 1994 to 2003 showed a three-
fold increase in resistance of Gram-positive organisms to 
ciprofloxacin (11.7% to 35.6%, P , 0.001) and oxacillin 





(11.6% to 36.7%, P = 0.001). S. aureus isolates demonstrated 
over a four-fold increase in resistance (8.7% to 36.7%) during 
the same time period.6
The report by Adebayo et al evaluated trends in antibi-
otic resistance of bacterial conjunctivitis isolates over an 
11.5-year period. There was an overall two-fold increase in 
resistance (24% to 45%) to erythromycin by Gram-positive 
isolates, with the most significant increases in S. aureus and 
alpha-hemolytic Streptococci (P , 0.0001). They observed 
a six-fold increase in resistance of the Gram-positive isolates 
group to ciprofloxacin (5% to 30%, P = 0.002), as well as 
the Gram-negative isolates group (1% to 16%, P = 0.0131). 
All isolates demonstrated low resistance to gatifloxacin and 
moxifloxacin (0% to 6%) until the last year, during which 
a 4–5-fold increase in resistance of the Gram-positive isolates 
were observed. Oxacillin exhibited an increase in resis-
tance of 2% to 40% (P , 0.0001) for S. aureus, reflecting 
a  significant increase in prevalence of MRSA.9
Classification of fluoroquinolones
Fluoroquinolones are synthetic fluorinated analogs of nali-
dixic acid. Nalidixic acid, the first antibacterial quinolone, was 
introduced in 1963 during chloroquine synthesis.  Quinolones 
block bacterial DNA synthesis by inhibiting the topoisomerase 
enzymes. DNA gyrase (topoisomerase II), the target of fluo-
roquinolone action in Gram-negative bacteria, is involved in 
supercoiling and uncoiling the double helix DNA of prokaryotes. 
Topoisomerase IV, the target in  Gram-positive bacteria, 
is involved in breaking the duplicated DNA of replicated 
prokaryotic DNA, preventing formation of daughter cells. 
By this mechanism, quinolones are rapidly bactericidal.26,27
Fourth-generation fluoroquinolones include gatifloxacin 
and moxifloxacin. They contain a substitution of a methoxy 
group at position 8 of the quinolone ring, which allows for 
simultaneous inhibition of both DNA gyrase and topoi-
somerase IV in Gram-positive bacteria.28,29 This structural 
modification was made specifically to increase potency 
against Gram-positive bacteria further while maintaining 
the broad spectrum of Gram-negative activity observed 
with the older fluoroquinolones.30 In vitro susceptibility 
testing demonstrates this increased sensitivity to the fourth-
 generation fluoroquinolones from S. aureus, coagulase-
negative  Staphylococci, and S. viridans isolates resistant to 
second- and third-generation fluoroquinolones.31
Functional and structural characteristics of the fourth-
 generation fluoroquinolones may reduce the chance of 
microbial resistance. In addition to providing broad-spectrum 
activity, dual targeting of topoisomerases reduces the risk of 
resistance because concomitant mutations in both genes are 
less likely to occur than a single mutation required to cause 
resistance to the older fluoroquinolones.32–36 The 8-methoxy 
fluoroquinolone structure reduces susceptibility to efflux from 
the bacterial cell, further decreasing the risk of resistance.37 
Two other mechanisms of bacterial resistance to fluoroquino-
lones include a change in permeability of the organism, and 
one that confers quinolone resistance in S. aureus.38
Gatifloxacin
Gatifloxacin is a fluoroquinolone co-developed by Kyorin and 
Bristol-Myers Squibb that has a 3-methylpiperazine group 
at position 7 of the quinolone ring and a methoxy group at 
 position 8. Gatifloxacin was approved in 1999 in the US as 
Tequin® (gatifloxacin, Bristol-Myers Squibb, New York, NY) 
for once-daily dosing therapy in acute bacterial exacerbation of 
chronic bronchitis, acute sinusitis, community-acquired pneu-
monia, pyelonephritis, gonorrhea, and complicated and uncom-
plicated cystitis.39 Systemic administration of  gatifloxacin, 
however, was strongly associated with hospitalization for 
hypoglycemia and hyperglycemia. With the exception of a 
slight increase in the risk of hypoglycemia with levofloxacin, 
this association was not shared by other  fluoroquinolones.40 
Several months following this report in 2006, Tequin was 
removed from the North American market.
Ophthalmic use
Development of ophthalmic gatifloxacin
A topical formulation of gatifloxacin called Zymar® (gati-
floxacin 0.3% [3 mg/mL], Allergan Labs, Irvine, CA) was 
introduced in 2003 for the treatment of acute bacterial con-
junctivitis in May 2010, the Food and Drug Administration 
approved a more concentrated formulation called Zymaxid™ 
(gatifloxacin 0.5% [5 mg/mL], Allergan Labs, Irvine, CA). 
Both are indicated for the treatment of bacterial conjunctivitis 
caused by susceptible organisms, and are also used in an off-
label manner in the treatment of bacterial keratitis and for 
prophylaxis of endophthalmitis following ocular surgery.29 
The most frequently reported adverse events related to both 
products were conjunctival irritation, increased lacrimation, 
keratitis, papillary conjunctivitis, and altered taste.41,42 There 
have been no reports of dysglycemia associated with topical 
gatifloxacin use.
Current studies
Nonapproved indications/in vitro studies
Oliveira et al compared in vitro minimum inhibitory con-
centrations (MICs) and susceptibility profiles for ofloxacin, 
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ciprofloxacin, gatifloxacin, and moxifloxacin in  Gram-positive 
and Gram-negative isolates from cases of keratitis, conjunctivitis, 
and endophthalmitis. The MICs for gatifloxacin and moxifloxa-
cin were significantly lower than for ciprofloxacin and ofloxacin 
for all Gram-positive organisms tested (S. aureus, methicillin-
resistant coagulase-negative Staphylococcus, methicillin-
susceptible coagulase-negative Staphylococcus, S. pneumoniae, 
S. viridans). For the  Gram-negative organisms tested (Hae-
mophilus species, P. aeruginosa, Serratia species, Moraxella 
species) ciprofloxacin and gatifloxacin had significantly lower 
MICs than moxifloxacin and ofloxacin.43
Kowalski et al compared susceptibilities to various 
fluoroquinolones of 20 isolates each of fluoroquinolone-
susceptible S. aureus, fluoroquinolone-resistant S. aureus, 
S. pneumoniae, and Haemophilus species. Moxifloxacin 
and gatifloxacin were the most potent against Gram-positive 
bacteria, and gatifloxacin and ciprofloxacin to be the most 
potent fluoroquinolones for Haemophilus species.44
Kowalski et al similarly reported susceptibility results 
from 177 keratitis isolates collected from 1993 to 2001. 
S. pneumoniae and S. viridans groups were more susceptible 
to moxifloxacin and gatifloxacin compared with ofloxacin and 
ciprofloxacin. The MICs of the fourth-generation fluoroqui-
nolones were significantly lower in all groups compared with 
levofloxacin and ciprofloxacin for Gram-positive  bacteria. 
Moxifloxacin did tend to have lower MICs compared with 
gatifloxacin against Gram-positive bacteria.  However, 
the MICs of gatifloxacin were significantly lower than 
 moxifloxacin for most Gram-negative bacteria tested.45
Mather et al examined susceptibility results from 93 bacterial 
endophthalmitis isolates. Coagulase-negative  Staphylococci 
were more susceptible (P = 0.02) to gatifloxacin and moxi-
floxacin than levofloxacin, ciprofloxacin, and ofloxacin. 
S. viridans was more susceptible (P = 0.02) to moxifloxacin, 
gatifloxacin, and levofloxacin than ciprofloxacin and ofloxacin. 
These authors also reported that moxifloxacin and gatifloxacin 
were equally potent for  second-generation fluoroquinolone-
resistant coagulase- negative Staphylococcus and Bacillus 
species.31  Comparative in vitro susceptibilities and MICs of 
ciprofloxacin,  gatifloxacin, and moxifloxacin against selected 
ocular pathogens have also been reviewed.46
Benzalkonium chloride (BAK) is a preservative found in 
many ophthalmic formulations, including gatifloxacin (Zymar 
and Zymaxid). BAK is a quaternary ammonium compound 
that has been consistently demonstrated to have synergistic 
antibacterial activity in vitro.47–51 It has been reported that 
the MICs of various organisms for gatifloxacin with BAK, 
organism eradication time, and  fluoroquinolone-resistant 
strains are significantly reduced when compared with 
unpreserved gatifloxacin, moxifloxacin, or other classes of 
fluoroquinolones. Romanowski et al published the results of 
a New Zealand white rabbit model of gatifloxacin-resistant 
S. aureus-induced keratitis. Four hours after bacterial inocu-
lation, the rabbit eyes were treated with gatifloxacin 0.3% 
plus 0.005% BAK, gatifloxacin 0.3% with BAK, BAK 
alone, or saline every 15 minutes for four hours. One hour 
after the end of treatment, the gatifloxacin + BAK group was 
noted to have significantly lower colony counts per cornea 
when compared with the group treated with gatifloxacin 
alone (P , 0.05). However, the mean colony-forming-unit 
(CFU) count with BAK alone was not significantly differ-
ent from the control group, suggesting there might have 
been some synergistic effect of gatifloxacin + BAK on the 
fluoroquinolone-resistant strain of MRSA.52,53
There has been some discussion regarding the speed of 
kill of certain classes of antibiotics especially as it relates to 
increasing efficacy and therefore decreasing days off school 
or work in patients with bacterial conjunctivitis. In addition, 
because of the off-label use of antibiotic prophylaxis prior 
to ocular surgery for the prevention of endophthalmitis, 
rapid speed of killing may be important in the immediate 
preoperative period. Hyon et al assessed the time-kill activity 
of Zymar (gatifloxacin 0.3%) and Vigamox® (moxifloxacin 
0.5%, Alcon Laboratories Inc, Fort Worth, TX) against 
isolates of S. aureus and coagulase-negative Staphylococ-
cus at 15 minutes, 30 minutes, and 60 minutes. The mean 
log CFU of Staphylococci recovered after incubation with 
gatifloxacin was significantly lower than after incubation 
with moxifloxacin at 15 minutes (mean 0.47 ± 1.12 log 
CFU/mL versus 4.55 ± 0.60 log CFU/mL), 30 minutes 
(mean 0.07 ± 0.31 log CFU/mL versus 3.82 ± 1.07 log 
CFU/mL), and 60 minutes (mean 0.00 ± 0.00 log CFU/mL 
versus 2.75 ± 1.29 log CFU/mL, P , 0.005). Similar results 
were seen against the coagulase-negative Staphylococci 
isolates.54 Callegan et al compared kill rates for Zymar and 
Vigamox against various isolates. Gatifloxacin was able to 
eradicate H. influenzae and S. pneumoniae completely in five 
minutes; MRSA, methicillin-resistant S. epidermidis, and 
fluoroquinolone-resistant S. epidermidis in 15 minutes; and 
S. aureus in 60 minutes. Moxifloxacin was able to eradicate 
S. pneumoniae by 60 minutes, but was unable to eradicate 
the other isolates completely by 60 minutes.55
In vitro susceptibility and resistance, in accordance with 
Clinical and Laboratory Standards Institute (CLSI) standards, 
are based on safe achievable concentrations in the serum after 
systemic administration. However, localized concentrations 





of fluoroquinolones have been shown to be higher than those 
achieved in the serum after systemic administration, even after 
only a few doses.56 In a rabbit keratitis model, corneas were 
inoculated with S. aureus isolates shown to be resistant to 
gatifloxacin (MIC 64 µg/mL), levofloxacin (MIC 32 µg/mL), 
and ciprofloxacin (MIC 256 µg/mL) based on CLSI standards. 
Despite in vitro resistance, aggressive treatment with Zymar, 
which is consistent with the typical and recommended dosing 
schedule for off-label keratitis treatment, significantly reduced 
the amount of viable S. aureus recovered from the corneas 
and significantly reduced the signs of infection compared with 
second- and third-generation fluoroquinolones, and was as 
effective as fortified cefazolin and vancomycin.57
Several studies have examined penetration of gatifloxa-
cin into ocular tissues and aqueous humor.58–62 In general, 
gatifloxacin is able to permeate tissue and get into the eye to 
some degree. However, it does not penetrate ocular tissues or 
achieve as high a concentration in aqueous as  moxifloxacin. 
In a rabbit model, mean moxifloxacin concentration in 
the conjunctiva was significantly higher than either levo-
floxacin (P = 0.0191) or gatifloxacin (P = 0.0236).63 This 
trend is repeatable in human studies. Aihara et al compared 
levofloxacin, gatifloxacin, and moxifloxacin levels in dis-
eased  pterygium tissue collected at 10, 30, and 45 minutes 
after a single dose. They found that the concentration of 
moxifloxacin was higher than for the other fluoroquino-
lones at all sample times, with a maximum concentration 
of 116.7 ± 28.9 µg/g at 10 minutes after instillation. At 
30  minutes, the mean concentrations of levofloxacin, gatiflox-
acin, and moxifloxacin were 11.3 ± 2.3 µg/g, 11.8 ± 3.9 µg/g, 
and 19.0 ± 6.3 µg/g, respectively.64 Wagner et al yielded 
comparable levofloxacin and gatifloxacin concentrations 
(2.34 µg/g and 2.54 µg/g, respectively) in healthy conjunctiva 
collected at 20 minutes after a single dose.65 Tordkildsen 
et al found peak mean concentration in conjunctiva from 
one drop of  besifloxacin, gatifloxacin, and moxifloxacin to 
be 2.30 ± 1.42 µg/g, 4.03 ± 3.84 µg/g, and 10.7 ± 5.89 µg/g, 
respectively.66 However, in the treatment of bacterial con-
junctivitis, where the infection is external to ocular tissue, a 
high degree of penetration may not be necessary.
In bacterial conjunctivitis
In Phase III trials of Zymar where patients were dosed for five 
days, gatifloxacin was found to be superior to its vehicle on days 
5–7 in patients with conjunctivitis and positive  conjunctival 
cultures. The clinical cure rate was reported to be 77% (40/52) 
for the gatifloxacin-treated group versus 58% (28/48) for 
the placebo-treated group. Also reported was a statistically 
superior eradication for causative pathogens of 92% (48/52) 
for gatifloxacin versus 72% (34/48) for placebo.41
A multicenter, investigator-masked, randomized clini-
cal trial comparing the efficacy of gatifloxacin ophthalmic 
solution 0.3% administered for five days either twice daily or 
four times daily in patients with acute bacterial conjunctivitis 
suggested that twice daily versus four times daily dosing had 
similar clinical cure rates within its intent-to-treat group and 
within its per-protocol group. In the twice daily group 86.5% 
(45/52) and in the four times daily group 71.2% (37/52) 
achieved clinical cure on day 5 (P = 0.096). However, this 
study was limited by its small population of patients.67
In Phase III trials of Zymaxid, patients with conjunctivitis 
and positive conjunctival cultures were dosed for five days. Clini-
cal outcomes for the trials demonstrated clinical success (resolu-
tion of conjunctival hyperemia and discharge) of 58% (193/333) 
for the gatifloxacin-treated groups versus 45% (148/325) for the 
vehicle-treated groups. Microbiological outcomes for the same 
clinical trials demonstrated a statistically superior eradication 
rate for causative pathogens of 90% (301/333) for gatifloxacin 
versus 70% (228/325) for the vehicle.42
The Charles T Campbell Eye Microbiology Labora-
tory at the University of Pittsburg continuously monitors 
antibiotic susceptibilities of organisms isolated from vari-
ous ocular infections (http://eyemicrobiology.upmc.com/ 
AntibioticSusceptibilities/Conjunctivitis.htm). They report 
that 100% of S. pneumoniae, Haemophilus species, Moraxella 
species, and Acinetobacter species cultured from patients with 
conjunctivitis and blepharitis were susceptible to gatifloxa-
cin and moxifloxacin. Coagulase-negative S taphylococcus 
isolates were 58% susceptible to both. S. aureus isolates were 
81% and 84% susceptible to gatifloxacin and moxifloxacin, 
respectively. Gram-negative organisms were extremely 
susceptible. Of all the Gram-negative cultures, a single 
isolate of P. aeruginosa was resistant to moxifloxacin, and 
a single isolate of Stenotrophomonas maltophilia was resis-
tant to both gatifloxacin and moxifloxacin. These data are 
specific to this region of the US, and are based on current 
CLSI breakpoint data for systemic dosing of susceptible, 
intermediate, and resistant MICs. It is assumed that with 
the higher concentrations of commercially available topical 
gatifloxacin and the potential to dose at a higher frequency 
than systemic gatifloxacin, the breakpoint MIC would be 
higher, and therefore, less bacteria would be intermediately 
or resistant to gatifloxacin. However, this hypothesis cannot 
be proven with current testing because “ocular” breakpoints 
do not exist. One thing is for certain, these in vitro data are 
not a direct indication of clinical efficacy.




Gatifloxacin for bacterial conjunctivitis
Conclusion
Bacterial conjunctivitis is a mostly self-limiting eye disease 
with rare permanent sequelae, even when left untreated. The 
role of antibiotic treatment is well described and allows for 
a shorter time to clinical and microbiological cure. When 
 therapy is warranted, cost, toxicity, and dosing frequency may 
influence the choice of antibiotic more than its potency.
Gatifloxacin ophthalmic solution is a fourth-generation 
fluoroquinolone with BAK preservative and broad-spectrum 
activity. It has had a relatively low resistance profile, but there 
are data suggesting that resistant strains based on systemic 
breakpoints are quickly rising. How these increased in vitro 
MIC findings affect clinical success or failure is not known, 
but it is an ominous trend. Because of this concern of selecting 
for resistant strains, and because many studies show equivalent 
results among various antibiotics in the treatment of bacterial 
conjunctivitis, it would be prudent to consider speed of kill, cost, 
toxicity, dosing frequency, antibacterial spectrum, and likely 
pathogen when deciding on which anti-infective treatment to 
initiate. Among the myriad of options, fluoroquinolones, includ-
ing gatifloxacin, can be considered an excellent option.
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